Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy

Trial Profile

Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2016

At a glance

  • Drugs Ixmyelocel-T (Primary)
  • Indications Cardiovascular disorders; Dilated cardiomyopathy; Heart failure
  • Focus Adverse reactions
  • Acronyms IMPACT-DCM
  • Sponsors Vericel Corporation
  • Most Recent Events

    • 03 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top